Company / Return on Assets (ROA)
Xeris Biopharma Holdings, Inc. Return on Assets (ROA) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
0.1%
FY2025
5-year range
-40.3% / 0.1%
FY2021-FY2025
Trend
+100.8%
vs FY2024
Sector context
#59 of 213
Health Care
What the data says
At 0.1%, Xeris Biopharma Holdings, Inc.'s return on assets (roa) ranks #59 of 213 in the Health Care sector. Return on Assets (ROA) has increased for 5 consecutive years, from -57.3% in FY2020 to 0.1% in FY2025.
Based on SEC 10-K filings.
0.1% in FY2025 with a 5-year CAGR of +57.4%.
Improved from -19.3% to 0.1% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +35.8pp
- 5-Year Change
- +57.4pp
- 10-Year Change
- -
Sector benchmark
#59 of 213 in Health CareTop 28% of 213This company 0.1% Sector average -24.1%
▼
+100.6% above sector average
Key checks
Key Insights
- Xeris Biopharma Holdings, Inc.'s return on assets (roa) has grown for 5 consecutive years.
- In FY2025, return on assets (roa) increased 100.8% year-over-year.
- Currently 24.3pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 0.1% | +100.8% |
| FY2024 | -17.0% | +12.1% |
| FY2023 | -19.3% | +45.8% |
| FY2022 | -35.6% | +11.7% |
| FY2021 | -40.3% | +29.6% |
| FY2020 | -57.3% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026